

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Lehrer-Graiver Joshua</u> (Last) (First) (Middle) C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 (Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Global Blood Therapeutics, Inc. [GBT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Medical Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/25/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/25/2019		M		312	A	\$12.95	312	D	
Common Stock	11/25/2019		S ⁽¹⁾		312	D	\$60	0	D	
Common Stock	11/25/2019		M		1,108	A	\$19.89	1,108	D	
Common Stock	11/25/2019		S ⁽¹⁾		1,108	D	\$60	0	D	
Common Stock	11/25/2019		M		3,515	A	\$27.9	3,515	D	
Common Stock	11/25/2019		S ⁽¹⁾		3,515	D	\$60	0	D	
Common Stock	11/25/2019		M		447	A	\$20	447	D	
Common Stock	11/25/2019		S ⁽¹⁾		447	D	\$60	0	D	
Common Stock	11/25/2019		M		298	A	\$19.89	298	D	
Common Stock	11/25/2019		S ⁽¹⁾		298	D	\$60	0	D	
Common Stock	11/25/2019		M		4,594	A	\$26.9	4,594	D	
Common Stock	11/25/2019		S ⁽¹⁾		4,594	D	\$60	0	D	
Common Stock	11/25/2019		M		656	A	\$26.9	656	D	
Common Stock	11/25/2019		S ⁽¹⁾		656	D	\$60	0	D	
Common Stock	11/26/2019		M		11,593	A	\$59.6	11,593	D	
Common Stock	11/26/2019		S ⁽¹⁾		11,593	D	\$67.19	0	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$12.95	11/25/2019		M			312	(2)	02/08/2026	Common Stock	312	\$0.00	625	D	
Stock Option (Right to Buy)	\$19.89	11/25/2019		M			1,108	(3)	09/07/2026	Common Stock	1,108	\$0.00	4,048	D	
Stock Option (Right to Buy)	\$27.9	11/25/2019		M			3,515	(4)	07/25/2027	Common Stock	3,515	\$0.00	5,469	D	
Stock Option (Right to Buy)	\$20	11/25/2019		M			447	(5)	08/10/2025	Common Stock	447	\$0.00	0	D	
Stock Option (Right to Buy)	\$19.89	11/25/2019		M			298	(3)	09/07/2026	Common Stock	298	\$0.00	3,750	D	
Stock Option (Right to Buy)	\$26.9	11/25/2019		M			4,594	(6)	02/16/2027	Common Stock	4,594	\$0.00	7,219	D	
Stock Option (Right to Buy)	\$26.9	11/25/2019		M			656	(6)	02/16/2027	Common Stock	656	\$0.00	6,563	D	
Stock Option (Right to Buy)	\$59.6	11/26/2019		M			11,593	(7)	01/31/2028	Common Stock	11,593	\$0.00	14,907	D	

Explanation of Responses:

- This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 9, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from July 26, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares of Common Stock underlying this option are fully vested.
- The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

/s/ Lesley Ann Calhoun, as
Attorney-in-Fact

11/27/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.